Melanoma patients (GSE91061 cohort) received Nivolumab treatment (anti-PD-1 anti-body) with high H3K4me3 score had significant overall survival (OS) and progression-free survival (PFS) advantages (Fig. 7A, B). Here, PDCD1 is linked to melanoma.